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Abstract
Transcranial magnetic stimulation (TMS), a research tool with various effects on brain cells,
can depolarize cerebral neurons noninvasively. This method offers temporal and spatial
resolution and can be combined with other neurocognitive and neuro-experimental
techniques. Prefrontal TMS therapy repeated daily for four to six weeks is a neuromodulation
technique approved by the US Food and Drug Administration for the treatment of major
depressive disorder (MDD) in patients resistant to medications. This technique utilizes
electromagnetic induction to excite neuronal cells. Several recent studies have enhanced our
understanding of this novel treatment intervention. This report reviews recent studies on the
mechanism of action, patient eligibility, effectiveness, and safety of TMS in treating
depression.
Categories: Internal Medicine, Neurology, Psychiatry
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Introduction And Background
Depression is a serious mental health condition characterized by a persistently depressed mood
and diminished interest in activities and can lead to severe functional impairment in daily life.
In diagnosing depression, the fifth edition of the Diagnostic and Statistical Manual of Mental
Disorders requires five or more symptoms to be present within a two-week period, with one of
these symptoms being a depressed mood or anhedonia (loss of interest or pleasure). Secondary
symptoms of major depression include changes in appetite and/or weight changes, sleep
difficulties (insomnia or hypersomnia), psychomotor agitation or retardation, fatigue or loss of
energy, diminished ability to think or concentrate, feelings of worthlessness or excessive guilt,
and suicidal ideation. The lifetime prevalence of depression in the general population has been
estimated to be 10% [1-2].
Major depressive disorder (MDD) is a highly prevalent psychiatric disorder with significant
morbidity and mortality. Psychotherapy, medications, and their combination are often
insufficient to control the symptoms of MDD, resulting in treatment-resistant depression
(TRD). This leads to poor functional outcomes in patients, including increased unemployment,
suicidal ideation, substance abuse, and unstable relationships. Transcranial magnetic
stimulation (TMS) has been successful in treating patients with TRD. A literature review
reported that the response rates to TMS range between 50% and 55%, and the remission rates
range between 30% and 35% in patients with major depression [3]. The dorsolateral prefrontal
cortex (DLPFC) is the part of the brain that has been reported dysregulated in patients with
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targets the pathophysiology of depression, using high-frequency electromagnetic induction
over the left DLPFC to effectively treat the behavioral dysregulation in patients with major
depression.
Review
TMS is an advanced treatment modality for patients with TRD, in which brief magnetic pulses
are applied to the brain, leading to cortical stimulation. Repetitive TMS (rTMS) consists of the
delivery of pulses in a repetitive fashion. TMS is a non-invasive technique, as it does not
require craniotomy or seizure induction to stimulate nerve cells [5]. Rather, TMS interconverts
electrical and magnetic energy to induce electromagnetic phenomena. An electromagnetic coil
is placed on the scalp, and an effective pulsatile magnetic field that depolarizes cortical
neurons is generated for a brief duration of time. This forceful magnetic field is generated on
the surface of the scalp, without any intrusion into the skin, muscles or bones, making its
electrical stimulation electrodeless [5-6]. Levels of excitability of neuronal stimulation can be
regulated, either by high (10 to 20 Hz) or low (1 Hz) frequency. The generated magnetic field is
about 1.5 Tesla, similar in strength to that of magnetic resonance imaging [7]. Patients being
treated with TMS undergo five daily treatment sessions over three to six weeks, resulting in a
total of 20 to 30 sessions during treatment.
High-frequency stimulation of the left DLPFC alleviates depressive symptoms, whereas low-
frequency cortical stimulation of the right DLPFC helps to relieve the symptoms of both
depression and anxiety. This was validated by a case series in which the effects of TMS on
either side of the prefrontal cortex were evaluated in 16 healthy individuals aged 24 to 75 years.
Patients who underwent stimulation of the left DLPFC showed a drop in salivary cortisol level
in the morning. However, the results of this study were limited due to the small sample size and
limited number of TMS sessions [6]. Many randomized clinical trials have shown that daily TMS
of the left prefrontal cortex was effective in treating depressive mood symptoms, with
remission rates of 30% to 40% of cases. Similar to antidepressants, TMS resulted in sustained
improvement in mood symptoms but with fewer side effects [5,8].
Another randomized multicenter trial showed that this non-invasive treatment method had
significant antidepressant effects with remission rates four-fold higher than placebo. A
multicenter observational study involving 307 patients in a clinical setting showed that the
depression severity scale decreased after treatment with TMS. Moreover, therapeutic responses
were maintained in patients treated with TMS [5,9-10]. TMS was found to significantly improve
all symptoms of depression on the Hamilton depression rating scale [11]. Another randomized,
controlled, multicenter, multiphase trial, performed at 23 sites worldwide, assessed the effects
of TMS in patients diagnosed with MDD and free of the side effects of any antidepressant. This
trial showed that patients who underwent TMS demonstrated clinically and statistically
significant improvements on the Montgomery-Asberg Depression Rating Scale (MASDR) after
four weeks; however, this outcome was similar to that observed in patients randomized to
placebo [5,12]. Another study provided descriptive evidence of the long-term therapeutic
benefits of TMS and maintenance of benefits with post-TMS antidepressant therapy [13].
The neurobiological phenomena underlying the effectiveness of TMS as an antidepressant are
not well understood, although studies have suggested a correlation between cerebral metabolic
activity and TMS effectiveness. This was validated by the results of TMS treatment in non-
responders who exhibited hypoperfusion in the frontal cortex. A pilot study involving 15
medication-resistant patients demonstrated an increase in cerebral blood volume during TMS.
Blood flow was measured at the beginning and end of each TMS session, with the frontal
hemoglobin concentration (fHbC) found to be associated with treatment outcomes, in that
increased fHbC during magnetic induction was inversely related to MASDR scores. This study
was limited due to the small sample size and because cerebral blood flow was not measured in
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the middle of treatment with TMS [14-15]. Neuronal physiology that responds to TMS is of
central importance, as repetitive stimulations increase synaptic plasticity, causing it to last
longer even after stimulation ceases. This result is contrary to the decrease in synaptic strength
observed in depression and may be attributed to the fact that fast rTMS (> 10 Hz) results in
neuronal excitation while slow rTMS (< 1 Hz) has the reverse effects. Another study reported
that daily sessions of TMS over the prefrontal cortex were found to increase cortical activity
and reduce activity in distant areas; moreover, cerebral blood flow at the stimulation site
decreased with increasing coil distance from the scalp to the outer cortex [16]. As
recommended, neuromodulation therapy via TMS is usually performed after failure of an
antidepressant trial, with or without psychotherapy.
Magnetoencephalography has provided insights into the possible role of neuronal circuits in
TMS-induced improvements in depression. This method found that clinical benefits of TMS in
depression are due, at least in part, to the functional connectivity of the left DLPFC with the
limbic system [17-19].
TMS is regarded as an effective and safe stimulation technique. However, it has a few side
effects that might affect treatment compliance. Commonly reported adverse effects include
transitory and/or recurrent headaches that respond to over the counter analgesics, a tingling
sensation on the scalp and face, and ipsilateral lacrimation. Seizure activity is rare, and one
patient was reported to develop trigeminal autonomic cephalalgia after the administration of
rTMS for refractory depression [20].
Conclusions
The clinical efficacy of TMS as an antidepressant has been well established. TMS is an
innovative and promising treatment modality for patients with TRD. Patient compliance,
however, may be affected, as TMS requires frequent visits to the clinic. Neuromodulation
through TMS may induce neurogenesis. Further research is required to explore its therapeutic
implementation and limitations, providing more effective treatment of patients with TRD.
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